Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.

نویسندگان

  • Stefan Kipfer
  • Marianne A Stephan
  • W M Michael Schüpbach
  • Pietro Ballinari
  • Alain Kaelin-Lang
چکیده

BACKGROUND It is unclear whether patients with different clinical subtypes of Parkinson disease (PD) differ in their risk of developing levodopa-induced dyskinesia (LID) and whether resting tremor is negatively correlated with this risk. OBJECTIVES To determine whether resting tremor as an initial manifestation of PD negatively correlated with subsequent occurrence and severity of LID and to study the correlations between LID and other epidemiological factors (eg, age at onset of PD and duration of PD). DESIGN Logistic regression analysis was used to determine predictive factors of LID. Spearman rank correlations between LID and epidemiological factors and motor signs (including tremor) were calculated. SETTING Institutional tertiary referral center for movement disorders. PATIENTS Cohort of 85 patients with PD. MAIN OUTCOME MEASURE Occurrence of LID according to the Unified Parkinson Disease Rating Scale part IV. RESULTS Resting tremor as an initial manifestation of PD was associated with reduced risk of developing LID independent of other predictors of LID (duration of PD, axial signs, and levodopa dose). CONCLUSION Resting tremor as an initial manifestation of PD predicts lower probability of developing LID under levodopa treatment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dissimilar mechanistic background of peripheral and orofacial hyperkinesia in patients with Parkinson’s disease and levodopa-induced dyskinesia

Introduction: Long-term levodopa treatment of Parkinson’s disease (PD) is frequently complicated by spontaneously occurring involuntary muscle movements called dyskinesia. The exact pathological mechanism of this complication has not yet been elucidated. We have previously demonstrated that in PD patients the vulnerability to develop peripheral but not orofacial dyskinesia is associated w...

متن کامل

Diabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study

Background and Objective: Dyskinesia is a debilitating complication of Parkinsonchr('39')s disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation. Materials and Methods: In this case-control study, ...

متن کامل

Surgical management of Parkinson's disease: a critical review.

Parkinson's disease is a progressive disabling movement disorder that is characterised by three cardinal symptoms: resting tremor, rigidity, and bradykinesia. Before the availability of effective medical treatment with levodopa and stereotactic neurosurgery, the objective of surgical management was to alleviate symptoms such as tremor at the expense of motor deficits. Levodopa was the first eff...

متن کامل

Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa

Parkinson's disease (PD) is a chronic progressive neurological disorder characterized by resting tremor, rigidity, bradykinesia, gait disturbance, and postural instability. Levodopa, the precursor to dopamine, coadministered with carbidopa or benserazide, aromatic amino acid decarboxylase inhibitors, is the most effective and widely used therapeutic agent in the treatment of PD. With continued ...

متن کامل

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)

Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal motor symptoms: resting tremor, rigidity, and bradykinesia. Since its introduction 40 years ago, levodopa has represented the gold standard for dopaminergic stimulation therapy in patients with PD. Levodopa is routinely combined with a dopa-decarboxylase inhibitor (DDCI) to prevent the conversion of levodopa into...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Archives of neurology

دوره 68 8  شماره 

صفحات  -

تاریخ انتشار 2011